Tissue-specific and reversible RNA interference in transgenic mice
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Genetically engineered mice provide powerful tools for understanding mammalian gene function. These models traditionally rely on gene overexpression from transgenes or targeted, irreversible gene mutation. By adapting the tetracycline (tet)-responsive system previously used for gene overexpression, we have developed a simple transgenic system to reversibly control endogenous gene expression using RNA interference (RNAi) in mice. Transgenic mice harboring a tet-responsive RNA polymerase II promoter driving a microRNA-based short hairpin RNA targeting the tumor suppressor Trp53 reversibly express short hairpin RNA when crossed with existing mouse strains expressing general or tissue-specific 'tet-on' or 'tet-off' transactivators. Reversible Trp53 knockdown can be achieved in several tissues, and restoring Trp53 expression in lymphomas whose development is promoted by Trp53 knockdown leads to tumor regression. By leaving the target gene unaltered, this approach permits tissue-specific, reversible regulation of endogenous gene expression in vivo, with potential broad application in basic biology and drug target validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the outcome of endogenous p53 reactivation can be senescence and/or cell death depending on the tumour type 35,141,142”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“Tet-regulated gene overexpression systems were initially developed for use in cultured cell”
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355 · cited 1×
“siRNA production was inhibited by addition of doxycycline to the drinking water, with no effect on the levels of the endogenous liver-specific microRNA miR-122 (ref”
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Self-citationSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Our results are generally consistent with recent studies from our group and other group”
Self-citationRestoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Our results are generally consistent with recent studies from our group and other group”
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“In developing this approach, we were concerned that the levels of tet transactivator produced in existing mouse strains would be insufficient to drive functional shRNA expression or, alternatively, that overexpression of the exogenous microRNA would saturate the RNAi machinery leading to off-target effects as has rece…”
Genetic transformation of mouse embryos by microinjection of purified DNA.
Gordon, J. W., Scangos, G. A., Plotkin, D. J., Barbosa, J. A., & Ruddle, F. H. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7380 · Cited by 1,435
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Conditional control of gene expression in the mouse
Lewandoski, M. (2001) · Nature Reviews Genetics · doi:10.1038/35093537 · Cited by 781
Cited by
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
“Animals Genotyping protocols of p53 / , INK4a/Arf / and TRE-shp53 mice were previously described (Dickins et al., 2007; Schmitt et al., 2002).”
BackgroundMethodSelf-citationPrinciples of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
“Third, RNAi can be readily applied to animal models (Dickins et al., 2007).”
Tumor Suppressive Functions of p53
Zilfou, J. T., & Lowe, S. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001883 · Cited by 575
“Similar data were reported through the utilization of an inducible RNAi-based strategy to reactivate p53 in in vitro and in vivo (Dickins et al. 2005; Dickins et al. 2007).”
MethodSelf-citationMarkstein, M., Pitsouli, C., Villalta, C., Celniker, S. E., & Perrimon, N. (2008) · Nature Genetics · doi:10.1038/ng.101 · Cited by 515
“For example, in a promising proof-of-principle experiment demonstrating inducible transgenic RNAi in the mous”
BackgroundGenetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
“Moreover, the development of systems for doxycycline-inducible shRNA expression in transgenic mice allows reversible expression of shRNAs in a time-and tissue-specific manner (Dickins et al , 2007; Premsrirut et al , 2011).”
Inside and out: the activities of senescence in cancer
Pérez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3773 · Cited by 462
Quantitative identification of senescent cells in aging and disease
Biran, A., Zada, L., Abou Karam, P., Vadai, E., Roitman, L., Ovadya, Y., Porat, Z., & Krizhanovsky, V. (2017) · Aging Cell · doi:10.1111/acel.12592 · Cited by 402
“First, we used a welldescribed system in which senescence is induced by reactivation of p53 (Dickins et al., 2005, 2007; Xue et al., 2007).”
MethodResultSelf-citationCheon, D.-J., & Orsulic, S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.154244 · Cited by 395
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
“Figure 1 the structures of 98n12-5(1), the five-tailed isomer of triethylenetetramine–laurylaminopropionate with a free internal amine, cholesterol, and mPeG2000-c14 Glyceride.”
BackgroundMethodInfluentialA Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference
Premsrirut, P. K., Dow, L. E., Kim, S. Y., Camiolo, M., Malone, C. D., Miething, C., Scuoppo, C., Zuber, J., Dickins, R. A., Kogan, S. C., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.012 · Cited by 315
“Several reports document that shRNA transgenic mice can be used to study gene function in vivo (Dickins et al., 2007; Seibler et al., 2007), although currently this approach is not widely used because the reliable generation of such animals remains a significant technical challenge.”
Self-citationAnimal models and therapeutic molecular targets of cancer: utility and limitations
Cekanova, M., & Rathore, K. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s49584 · Cited by 274
“Genetically modified mice are created by microinjection of DNA in the pronuclei of fertilized zygotes and the transgene is integrated into the genome.(37,38) Transgenic mice generated to carry cloned oncogenes(39) and knockout mice lacking tumor suppressor genes(40) have provided good models of human cancer.”
Autonomous role of medullary thymic epithelial cells in central CD4+ T cell tolerance
Hinterberger, M., Aichinger, M., Prazeres da Costa, O., Voehringer, D., Hoffmann, R., & Klein, L. (2010) · Nature Immunology · doi:10.1038/ni.1874 · Cited by 261
“Unlike ‘naked’ short hairpins, whose transcription requires RNA Polymerase III (Pol III) promoters, transcription of such ‘designer’ miRNAs is driven by Pol II promoters, thus offering the potential for tissue-specific or temporally controlled gene silencing in vivo 25-26 .”
Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia
Greene, C., Kealy, J., Humphries, M. M., Gong, Y., Hou, J., Hudson, N., Cassidy, L. M., Martiniano, R., Shashi, V, Hooper, S. R., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.156 · Cited by 235
Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay
Fellmann, C., Zuber, J., McJunkin, K., Chang, K., Malone, C. D., Dickins, R. A., Xu, Q., Hengartner, M. O., Elledge, S. J., Hannon, G. J., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.008 · Cited by 222
“…miRNA-mimetics provide a versatile tool for long-term gene suppression in vitro and in vivo, as well as pool-based RNAi screening (see, for example, Dickins et al., 2007; Schlabach et al., 2008; Silva et al., 2008; Zender et al., 2008; Zuber et al., 2011). olecular Cell 41, 733–746, March 18, 2011…”
Self-citationLoss-of-function genetic tools for animal models: cross-species and cross-platform differences
Housden, B. E., Muhar, M., Gemberling, M., Gersbach, C. A., Stainier, D. Y. R., Seydoux, G., Mohr, S. E., Zuber, J., & Perrimon, N. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.118 · Cited by 220
Tumour suppression by p53: the importance of apoptosis and cellular senescence
Zuckerman, V., Wolyniec, K., Sionov, R. V., Haupt, S., & Haupt, Y. (2009) · The Journal of Pathology · doi:10.1002/path.2584 · Cited by 170
“The observation that p53 restoration in lymphomas causes cancer regression was supported by Dickins et al [104], who used the RNAi strategy to reset active p53 in tumours.”
MethodUBF levels determine the number of active ribosomal RNA genes in mammals
Sanij, E., Poortinga, G., Sharkey, K., Hung, S., Holloway, T. P., Quin, J., Robb, E., Wong, L. H., Thomas, W. G., Stefanovsky, V., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200805146 · Cited by 210
“UBF belongs to the sequence-nonspecifi c class of high mobility group (HMG) proteins and appears to function exclusively in Pol I transcription (for review see Moss et al., 2007 ).”
Genetically Engineered Mouse Models in Cancer Research
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06004-5 · Cited by 206
MicroRNA: an Emerging Therapeutic Target and Intervention Tool
Liu, Z., Sall, A., & Yang, D. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9060978 · Cited by 173
“Recently, tissue specific and reversible gene silencing in vivo has been achieved using the miRNA-based RNAi triggers in transgenic mice [125].”
BackgroundAnimal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development
(2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00035 · Cited by 171
“101 GFAP-dependent gene overexpression or silencing in HSCs may also be combined with the tetracycline-responsive system (TRE) to reversibly control gene expression.(102) In many cell types, including HSCs, tumor suppressor p53 participates in senescence.”
BackgroundRapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization
Senturk, S., Shirole, N. H., Nowak, D. G., Corbo, V., Pal, D., Vaughan, A., Tuveson, D. A., Trotman, L. C., Kinney, J. B., & Sordella, R. (2017) · Nature Communications · doi:10.1038/ncomms14370 · Cited by 166
“Hence, we sought to improve on existing CRISPR/Cas9 techniques to generate a system that (1) would provide potent, robust and temporally controlled gene editing, (2) be applicable to a broad spectrum of cell types and tissues, (3) facilitate highthroughput manipulation and (4) be traceble.”
Stable RNA interference rules for silencing
Fellmann, C., & Lowe, S. W. (2014) · Nature Cell Biology · doi:10.1038/ncb2895 · Cited by 163
Self-citationA pipeline for the generation of shRNA transgenic mice
Dow, L. E., Premsrirut, P. K., Zuber, J., Fellmann, C., McJunkin, K., Miething, C., Park, Y., Dickins, R. A., Hannon, G. J., & Lowe, S. W. (2012) · Nature Protocols · doi:10.1038/nprot.2011.446 · Cited by 159
“In terms of shRNA delivery, the most basic options—viral transduction and pronuclear transgenesis—require minimal vector construction and little or no ES cell manipulation, but, in our experience, they require extensive screening of many founder lines to identify those with efficient knockdow”
BackgroundSelf-citationGenerating mouse models for biomedical research: technological advances
Gurumurthy, C. B., & Lloyd, K. C. K. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.029462 · Cited by 180
“Subsequently, knockdown micewere generated using standard pronuclear injection of constructs that express short-hairpin RNAs (shRNA; Box 1) (Chang et al., 2004; Peng et al., 2006; Seibler et al., 2007; Dickins et al., 2007).”
BackgroundMethodUnderstanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
“Unlike xenograft models, genetically engineered mouse models (GEMMs) develop orthotopic tumours in immune-proficient environments and with molecular features similar to their clini - cal counterparts 39,40 .”
Airway remodeling in asthma: New mechanisms and potential for pharmacological intervention
Girodet, P., Ozier, A., Bara, I., de Lara, J.-M. T., Marthan, R., & Berger, P. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.02.001 · Cited by 148
Polycomb Repressive Complex 2 (PRC2) Restricts Hematopoietic Stem Cell Activity
Majewski, I. J., Blewitt, M. E., de Graaf, C. A., McManus, E. J., Bahlo, M., Hilton, A. A., Hyland, C. D., Smyth, G. K., Corbin, J. E., Metcalf, D., et al. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060093 · Cited by 131
“shRNAmir constructs (pSM2) that target Suz12 (A: V2MM_96046 or B: V2MM_196969), Ezh2 (A: V2MM_35988 or B: V2MM_25325), and a nonspecific sequence (Nons) were obtained from Open Biosystems, and the hairpin sequence was subcloned into the LMS/LMP vectors [65,66].”
MethodLin28b promotes fetal B lymphopoiesis through the transcription factor Arid3a
Zhou, Y., Li, Y.-S., Bandi, S. R., Tang, L., Shinton, S. A., Hayakawa, K., & Hardy, R. R. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141510 · Cited by 127
“The retroviral vector LMP from GE Healthcare was used to express the shRNAmir construct from RNA Polymerase II (Pol II) promoters (Dickins et al., 2005, 2007).”
MethodRadiation‐induced bystander effects in vivo are epigenetically regulated in a tissue‐specific manner
Ilnytskyy, Y., Koturbash, I., & Kovalchuk, O. (2008) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20440 · Cited by 136
“Importantly, both DNA methylation [Ehrlich, 2003] and regulatory microRNAs [Callis et al., 2007; Dickins et al., 2007; Makeyev and Maniatis, 2008] govern tissue-specific gene expression and function.”
BackgroundHow Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K., & Pao, W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 123
Gutiérrez‐Aguilar, M., Douglas, D. L., Gibson, A. K., Domeier, T. L., Molkentin, J. D., & Baines, C. P. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.04.008 · Cited by 127
“PiC shRNA TG mice were generated as described previously [21].”
MethodA Nanobody-Based System Using Fluorescent Proteins as Scaffolds for Cell-Specific Gene Manipulation
Tang, J. C. Y., Szikra, T., Kozorovitskiy, Y., Teixiera, M., Sabatini, B. L., Roska, B., & Cepko, C. L. (2013) · Cell · doi:10.1016/j.cell.2013.07.021 · Cited by 122
“This system can be used for gene overexpression and gene deletion (Figures 4, 5, 6, and 7) and should be able to perform RNA interference (RNAi) knock-down (Dickins et al., 2007; Dietzl et al., 2007).”
MethodShi, J., Wang, E., Zuber, J. A., Rappaport, A., Taylor, M. J., Johns, C., Lowe, S. W., & Vakoc, C. R. (2012) · Oncogene · doi:10.1038/onc.2012.110 · Cited by 125
Self-citationModeling metastasis in the mouse
Bos, P. D., Nguyen, D. X., & Massagué, J. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.003 · Cited by 136
Rad51 supports triple negative breast cancer metastasis
Wiegmans, A. P., Al‐Ejeh, F., Chee, N., Yap, P.-Y., Gorski, J. J., Silva, L. M. D., Bolderson, E., Chenevix‐Trench, G., Anderson, R. L., Simpson, P. T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1923 · Cited by 111
“2 cell as described previously by Dickins et al.[40].”
MethodKim, M. Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_9 · Cited by 119
Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing
Beisel, C. L., Chen, Y. Y., Culler, S. J., Hoff, K. G., & Smolke, C. D. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq954 · Cited by 100
“We also compared the quantitative response properties of our ligand-responsive miRNA system to the tet inducible promoter system, which is often used in conditional gene silencing (27).”
Mountford, J. K., Petitjean, C., Putra, H. W. K., McCafferty, J. A., Setiabakti, N. M., Lee, H., Tønnesen, L. L., McFadyen, J. D., Schoenwaelder, S. M., Eckly, A. E., et al. (2015) · Nature Communications · doi:10.1038/ncomms7535 · Cited by 100
Self-citationRNAi and Gene Therapy: A Mutual Attraction
Grimm, D., & Kay, M. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.473 · Cited by 102
“Finally, in this area, Dickins et al recently reported the first transgenic mice harboring an inducible and tissuespecific RNAi expression cassette.(64) Spatio-temporal RNAi transgenesis is a groundbreaking approach which will find numerous broad uses in basic research or in preclinical disease models.”
BackgroundA modular and flexible ESC-based mouse model of pancreatic cancer
Saborowski, M., Saborowski, A., Morris, J. P., Bosbach, B., Dow, L. E., Pelletier, J., Klimstra, D. S., & Lowe, S. W. (2014) · Genes & Development · doi:10.1101/gad.232082.113 · Cited by 75
“Using shRNAs, we showed that gene suppression by RNAi can mimic loss of gene function in mice (Hemann et al. 2003; Dickins et al. 2005, 2007) and, more recently, adopted an efficient transgenesis approach that implements a recombinase-mediated cassette exchange strategy (RCME) to introduce…”
MethodSelf-citationMutsaers, A. J., Ng, A. J. M., Baker, E. K., Russell, M. R., Chalk, A. M., Wall, M., Liddicoat, B. J. J., Ho, P. W. M., Slavin, J. L., Goradia, A., et al. (2013) · Bone · doi:10.1016/j.bone.2013.02.016 · Cited by 74
“These have demonstrated efficacy in hematopoietic tumors but have not to date been reported in solid tumor models [13, 14].”
BackgroundMethodInfluentialSelf-citationHagen, J., Young, N. D., Every, A. L., Pagel, C. N., Schnoeller, C., Scheerlinck, J. Y., Gasser, R. B., & Kalinna, B. H. (2014) · Nature Communications · doi:10.1038/ncomms6375 · Cited by 72
Onyido, E. K., Sweeney, E., & Nateri, A. S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0541-3 · Cited by 71
“The study of loss-of gene function is also applicable in mouse models by performing mouse conditional gene mutation [173], mouse gene knock-outs (KO) [174, 175], mouse single cell knock-outs [176] and mouse models for RNA interference [177, 178].”
BackgroundEngineering of Synthetic Mammalian Gene Networks
Weber, W., & Fussenegger, M. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.005 · Cited by 75
A system for Cre-regulated RNA interference in vivo
Stern, P., Astrof, S., Erkeland, S. J., Schustak, J., Sharp, P. A., & Hynes, R. O. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806907105 · Cited by 62
“These strategies allow reversible ‘‘on–off’’ regulation of RNAi expression in vivo but rely on a limited (although expanding) set of tissuespecific tet-transactivator mice (13).”
BackgroundOttina, E., Grespi, F., Tischner, D., Soratroi, C., Geley, S., Ploner, A., Reichardt, H. M., Villunger, A., & Herold, M. J. (2012) · Blood · doi:10.1182/blood-2011-12-399089 · Cited by 61
“To generate an inducible lentiviral construct containing an eGFP marker the previously reported FUGW vector (21) was modified by inserting the PCR-amplified TRE-miR-A1 cassette using above-mentioned TMP miR30-A1 vector upstream of the human ubiquitin promoter (Ubi-P)-driven eGFP cassette by Pac1.”
MethodInfluentialAcute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma
Lee, C., Castle, K. D., Moding, E. J., Blum, J. M., Williams, N. T., Luo, L., Ma, Y., Borst, L. B., Kim, Y., & Kirsch, D. G. (2015) · Nature Communications · doi:10.1038/ncomms9477 · Cited by 59
The Polycomb Protein Ezh2 Impacts on Induced Pluripotent Stem Cell Generation
Ding, X., Wang, X., Sontag, S., Qin, J., Wanek, P., Lin, Q., & Zenke, M. (2013) · Stem Cells and Development · doi:10.1089/scd.2013.0267 · Cited by 69
TLR Regulation of SPSB1 Controls Inducible Nitric Oxide Synthase Induction
Lewis, R. S., Kolesnik, T. B., Kuang, Z., D’Cruz, A. A., Blewitt, M. E., Masters, S. L., Low, A., Willson, T., Norton, R. S., & Nicholson, S. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002993 · Cited by 57
“Annealed oligonucleotides were subsequently subcloned into the LMP vector by virtue of the XhoI and EcoRI overhangs (35, 36).”
MethodA biotin-triggered genetic switch in mammalian cells and mice
Weber, W., Lienhart, C., Baba, M. D., & Fussenegger, M. (2009) · Metabolic Engineering · doi:10.1016/j.ymben.2008.12.001 · Cited by 61
Liu, X., Fang, H., Chen, H., Jiang, X., Fang, D.-R., Wang, Y., & Zhu, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038659 · Cited by 52
“Recent reports demonstrated that embedding a shRNA in the context of a naturally occurring Pol II-driven miRNA transcript increases the flexibility of RNAi allowing for conditional and cell type-specific expression [17,18].”
BackgroundWang, J., Deng, R., Chen, S., Deng, S., Hu, Q., Xu, B., Li, J., He, Z., Peng, M., Lei, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108414 · Cited by 60
Mouse models of medulloblastoma
Wu, X., Northcott, P. A., Croul, S. E., & Taylor, M. D. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10040 · Cited by 59
Conditional RNAi: Towards a silent gene therapy
Lee, S., & Kumar, P. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.016 · Cited by 50
Reversible suppression of an essential gene in adult mice using transgenic RNA interference
McJunkin, K., Mazurek, A., Premsrirut, P. K., Zuber, J., Dow, L. E., Simon, J., Stillman, B., & Lowe, S. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104097108 · Cited by 49
Self-citationCorrection: An RNAi-Based Approach to Down-Regulate a Gene Family In Vivo
Kim, J., Badaloni, A., Willert, T., Zimber‐Strobl, U., hn, R. K. ⁄., Wurst, W., & Kieslinger, M. (2013) · PLoS ONE · doi:10.1371/annotation/c8b2e360-b78a-4c2f-a1a3-c53325f18211 · Cited by 48
PTEN action in leukaemia dictated by the tissue microenvironment
Miething, C., Scuoppo, C., Bosbach, B., Appelmann, I., Nakitandwe, J., Ma, J., Wu, G., Lintault, L., Auer, M., Premsrirut, P. K., et al. (2014) · Nature · doi:10.1038/nature13239 · Cited by 45
Self-citationConditional gene expression systems in the transgenic rat brain
Schönig, K., Weber, T., Frömmig, A., Wendler, L., Pesold, B., Djandji, D., Bujard, H., & Bartsch, D. (2012) · BMC Biology · doi:10.1186/1741-7007-10-77 · Cited by 44
“Moreover, as depicted here with the newly developed Cre reporter line, the Cre/loxP technology can be employed for the tissue-specific overexpression of transgenes or alternatively for the knockdown of endogenous gene activities using polymerase II controlled small hairpin RNAs [53,54].”
Recent advances in the development of new transgenic animal technology
Miao, X. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1081-7 · Cited by 49
“The triple transgenic mice were administered tetracycline to activate the tTA system to bind with the promoter and TRE, and ultimately activate RNAi [77].”
Review article Genetically modified animals for use in research and biotechnology
Chaible, L. M., Corat, M. A. F., Abdelhay, E., & Dagli, M. L. (2010) · Genetics and Molecular Research · doi:10.4238/vol9-3gmr867 · Cited by 43
Schönig, K., Bujard, H., & Gossen, M. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(10)77022-1 · Cited by 41
Genetically Engineered Mouse Models for Drug Development and Preclinical Trials
Lee, H. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2014.074 · Cited by 50
“Inducible RNAi technologies were devised and implemented to reduce the risk of such side effects (Dickins et al., 2007; Seibler et al., 2007; McJunkin et al., 2011; Zuber et al., 2011a).”
MethodLi, G., Chang, H., Zhai, Y., & Xu, W. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.9.4943 · Cited by 41
Inducible Transgenic Rat Model for Diabetes Mellitus Based on shRNA-Mediated Gene Knockdown
Kotnik, K., Popova, E., Todiraş, M., Mori, M. A., Alenina, N. V., Seibler, J., & Bäder, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005124 · Cited by 42
“Recently, systems allowing tetracycline inducible shRNA or microRNA expression have been proven to be safe, controllable, and effective tools for gene inhibition in mice [14,15].”
BackgroundMethodModeling human osteosarcoma in the mouse: From bedside to bench
Janeway, K. A., & Walkley, C. R. (2010) · Bone · doi:10.1016/j.bone.2010.07.028 · Cited by 43
“The application of in vivo shRNA to these models also bears consideration as a means to model therapeutic effect with regulatable hairpin systems that would allow effects of gene loss of function on initiation and maintenance of OS to be established [90,91].”
MethodSelvadurai, M. V., Moon, M. J., Mountford, S. J., Ma, X., Zheng, Z., Jennings, I. G., Setiabakti, N. M., Iman, R. P., Brazilek, R. J., Abidin, N. A. Z., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aar8430 · Cited by 37
“We used a cytomegalovirus (CMV)–driven and tet-regulated system to induce expression of microRNA-based short hairpin RNAs (shRNAs) (12, 13) against PI3KC2.”
MethodGlover, J. D., Taylor, L., Sherman, A., Zeiger-Poli, C., Sang, H., & McGrew, M. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077222 · Cited by 44
Liu, X.-Y., Tang, Q., Chen, H., Jiang, X., & Fang, H. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.5425 · Cited by 33
Molokanova, O., Schönig, K., Weng, S., Wang, X., Bros, M., Diken, M., Ohngemach, S., Karsdal, M. A., Strand, D. J., Nikolaev, A., et al. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.11.002 · Cited by 35
Takiguchi, M., Dow, L. E., Prier, J. E., Carmichael, C., Kile, B. T., Turner, S. J., Lowe, S. W., Huang, D. C. S., & Dickins, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054009 · Cited by 32
“transactivator expression is controlled by the largely hematopoietic-specific Em or Vav promoters [8,21,22].”
BackgroundSelf-citationInducible Gene and shRNA Expression in Resident Hematopoietic Stem Cells In Vivo
Laurenti, E., Barde, I., Verp, S., Offner, S., Wilson, A., Quenneville, S., Wiznerowicz, M., MacDonald, H. R., Trono, D., & Trumpp, A. (2010) · Stem Cells · doi:10.1002/stem.460 · Cited by 41
An inducible RNA interference system for the functional dissection of mouse embryogenesis
Vidigal, J. A., Morkel, M., Wittler, L., Brouwer-Lehmitz, A., Grote, P., Macura, K., & Herrmann, B. G. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq199 · Cited by 32
“Other vector-based RNAi systems have been used in adult mice (7–9); however, embryonic phenotypes were not reported.”
BackgroundPDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Ellwood‐Yen, K., Keilhack, H., Kunii, K., Dolinski, B. M., Connor, Y., Hu, K., Nagashima, K., O’Hare, E., Erkul, Y., Bacco, A. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2282 · Cited by 32
Neuron-specific Sumo1–3 knockdown in mice impairs episodic and fear memories
Wang, L., Rodriguiz, R. M., Wetsel, W. C., Sheng, H., Zhao, S., Liu, X., Paschen, W., & Yang, W. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130148 · Cited by 37
“Several strategies have been developed to generate inducible and reversible RNAi transgenic mice.(25,26) In these mice, the tetracycline response element system was used to regulate the expression of short hairpin RNAs (shRNAs).”
BackgroundRecombinase-based conditional and reversible gene regulation via XTR alleles
Robles-Oteíza, C., Taylor, S., Yates, T. J., Cicchini, M., Lauderback, B., Cashman, C. R., Burds, A. A., Winslow, M. M., Jacks, T., & Feldser, D. M. (2015) · Nature Communications · doi:10.1038/ncomms9783 · Cited by 33
“This approach has been used to regulate the expression of three tumor suppressor genes (Apc, Pten, and p53) in relevant cancer models 5, 6, 31, 33, 34 .”
Genetically engineered mouse models for studying radiation biology
Castle, K. D., Chen, M., Wisdom, A. J., & Kirsch, D. G. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.06.19 · Cited by 33
“In order to model the temporary loss of p53 that would occur with a p53 inhibitor, we utilized the tetracycline-responsive element (TRE) to drive the in vivo expression of a shRNA against p53 (17,18).”
MethodDeveloping tTA Transgenic Rats for Inducible and Reversible Gene Expression
Zhou, H., Huang, C., Yang, M., Landel, C. P., Xia, P. Y., Liu, Y., & Xia, X. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.171 · Cited by 29
“Recent advances in transgenic RNAi indicates that RNAi-mediated gene silencing can reproduce phenotypes of the gene knockout [37, 51, 52].”
BackgroundA dynamic perspective of RNAi library development
Pan, Q., van der Laan, L. J. W., Janssen, H. L. A., & Peppelenbosch, M. P. (2012) · Trends in biotechnology · doi:10.1016/j.tibtech.2012.01.002 · Cited by 32
Systemic siRNA delivery to leukocyte-implicated diseases
Peer, D., & Shimaoka, M. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7936 · Cited by 29
Regulation of BDNF Release by ARMS/Kidins220 through Modulation of Synaptotagmin-IV Levels
López‐Benito, S., Sánchez-Sánchez, J., Brito, V., Calvo-Enrique, L., Lisa, S., Torres-Valle, M., Palko, M. E., Vicente‐García, C., Fernández-Fernández, S., Bolaños, J. P., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1653-17.2018 · Cited by 31
“Generation of a new conditional ARMS mouse model To address the role of ARMS in BDNF release in vivo, we generated a new mouse model lacking ARMS using an RNA interference strategy (Dickins et al., 2007) (see Material and Methods).”
MethodAbate-Shen, C. T., Brown, P. H., Colburn, N. H., Gerner, E. W., Green, J. E., Lipkin, M., Nelson, W. G., & Threadgill, D. W. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0076 · Cited by 29
Berger, S. M., Pesold, B., Reber, S., Schönig, K., Berger, A. J., Weidenfeld, I., Miao, J., Berger, M. R., Gruß, O. J., & Bartsch, D. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq616 · Cited by 31
“Although recent publications show reversibility of miRNA-mediated gene inactivation in transgenic mice within a period of days, this was observed in highly proliferative, oncogenic B-lymphocytes (45).”
BackgroundObeid, M. A., Dufès, C., Somani, S., Mullen, A. B., Tate, R. J., & Ferro, V. A. (2018) · Journal of Liposome Research · doi:10.1080/08982104.2018.1531424 · Cited by 30
“This is in agreement with what has been reported in the literature about the reversibility of the RNAi mechanism [33, 34].”
ResultA Pipeline for Drug Target Identification and ValidationPreprint
Manchado, E., Huang, C., Tasdemir, N., Tschaharganeh, D. F., Wilkinson, J. E., & Lowe, S. W. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031096 · Cited by 29
“…we use miR30-based shRNA systems that enable robust gene knockdown from constitutive and inducible promoters and that link the shRNAs to fluorescent reporters, allowing the facile tracking and/or sorting of shRNA-expressing cells (Hemann et al. 2003; Dickins et al. 2005, 2007; Zuber et al. 2011a).”
MethodSelf-citationOptoribogenetic control of regulatory RNA molecules
Pilsl, S., Morgan, C., Choukeife, M., Möglich, A., & Mayer, G. (2020) · Nature Communications · doi:10.1038/s41467-020-18673-5 · Cited by 25
Generating Genetically Modified Mice: A Decision Guide
Huijbers, I. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7169-5_1 · Cited by 25
Conditional gene silencing in mammalian cells mediated by a stress-inducible promoter
Yang, W., & Paschen, W. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.011 · Cited by 30
The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3
Vaughan, C. A., Singh, S., Subler, M. A., Windle, J. J., Inoue, K., Fry, E. A., Pillappa, R., Grossman, S. R., Windle, B. E., Yeudall, W. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20928-8 · Cited by 25
Controlled insertional mutagenesis using a LINE-1 ( ORFeus ) gene-trap mouse model
O’Donnell, K. A., An, W., Schrum, C. T., Wheelan, S. J., & Boeke, J. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302504110 · Cited by 29
What a Fish Can Learn from a Mouse: Principles and Strategies for Modeling Human Cancer in Mice
Bailey, J. M., Creamer, B. A., & Hollingsworth, M. A. (2009) · Zebrafish · doi:10.1089/zeb.2009.0626 · Cited by 22
“54 To mimic the heterogenous and complex genetic nature of tumors, investigators have developed shRNA screens to target pools of genes known to promote hepato-carcinogenesis.”
Anticancer therapeutics: A surge of new developments increasingly target tumor and stroma
Broxterman, H. J., & Georgopapadakou, N. H. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.07.001 · Cited by 23
Accelerating Cancer Modeling with RNAi and Nongermline Genetically Engineered Mouse Models
Livshits, G., & Lowe, S. W. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069856 · Cited by 23
“2008) and tetracycline-inducible promoters (Dickins et al. 2007).”
Self-citationRNA interference screening demystified
Lord, C. J., Martin, S. A., & Ashworth, A. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.058735 · Cited by 21
“screens in cultured cells. Already, individual genes can be targeted in mice using RNAi,”
BackgroundHarary, P. M., Rajaram, S., Chen, M. S., Hori, Y. S., Park, D. J., & Chang, S. D. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02270-2 · Cited by 22
Golding, M. C., & Mann, M. R. W. (2011) · Gene Therapy · doi:10.1038/gt.2011.26 · Cited by 20
Conditional RNA interference in mammalian cells via RNA transactivation
Zhou, Y., Sheng, P., Li, J., Li, Y., Xie, M., & Green, A. A. (2024) · Nature Communications · doi:10.1038/s41467-024-50600-w · Cited by 16
INK4a/ARF limits the expansion of cells suffering from replication stress
Monasor, A., Murga, M., Lopez-Contreras, A. J., Navas, C., Goméz-López, G., Pisano, D. G., & Fernández-Capetillo, Ó. (2013) · Cell Cycle · doi:10.4161/cc.25017 · Cited by 18
“INK4a/Arf targeting shRNAs were previously validated in several studies.(26,27) Retroviral infections were done using standard procedures, and infected MEFs were selected with puromycin (2 μg/ml) for 3 d.”
MethodIn situ administration of cytokine combinations induces tumor regression in mice
Zhang, J., Jiang, H., & Zhang, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.050 · Cited by 16
“Inducible expression systems have been used to evaluate the influences of some genes or siRNAs on tumor development (12-15).”
MethodRNA interference-based technology: what role in animal agriculture?
Bradford, B. J., Cooper, C. A., Tizard, M. L., Doran, T. J., & Hinton, T. M. (2016) · Animal Production Science · doi:10.1071/an15437 · Cited by 17
“This can be overcome by decreasing the strength of the promoter, incorporating the shRNA into an endogenous miRNA intron or using tissue-specific or transducible promoters (Furth et al. 1994; Dickins et al. 2007).”
BackgroundGene Targeting to the Stroma of the Prostate and Bone
Jackson, R. S., Franco, O. E., & Bhowmick, N. A. (2008) · Differentiation · doi:10.1111/j.1432-0436.2008.00273.x · Cited by 16
“Examples of such transgenes include Cre (Lewandoski, 2001) and targeting inserts for RNA interference (RNAi) mediated gene knockdown (Dickins et al., 2007).”
Background
Metadata
- Authors
- Dickins, R. A., McJunkin, K., Hernando, E., Premsrirut, P. K., Krizhanovsky, V., Burgess, D. J., Kim, S. Y., Cordon-Cardo, C., Zender, L., Hannon, G. J., & Lowe, S. W.
- Affiliations
- Howard Hughes Medical Institute (US)
- Cold Spring Harbor Laboratory (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Lowe, Scott W
- ORCID
- Venue
- Nature Genetics
- Published
- 2007-06-17
- Volume
- 39
- Issue
- 7
- Pages
- 914-921
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC4595852
- OpenAlex
- W2169151715
- Cited by
- 174
- References
- 39
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 8 · 2016: 6 · 2015: 12 · 2014: 17 · 2013: 19 · 2012: 14
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- National Cancer Institute (P01CA087497, P01CA013106, P30CA008748)
- National Institute of General Medical Sciences (T32GM008444)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- RNA interference, shRNA, microRNA, Trp53, tissue-specific gene regulation, lymphoma, tumor regression, transgenic mice, endogenous gene expression
- MeSH terms
- Animals, Mice, Transgenic, Organ Specificity, Promoter Regions, Genetic, Tetracycline, Drug Delivery Systems, RNA Interference, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.